Business Context and Reporting Period
Company: CG Oncology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 5, 2024
Event: Disclosure of topline data from the BOND-003 Phase 3 clinical trial for cretostimogene (CG0070) as monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The primary material event is the release of topline data from the BOND-003 trial as of the September 30, 2024 data cutoff:
- Complete Response (CR) at Any Time: 74.5% (82 out of 110 patients; 95% CI: 65.4-82.4%).
- CR Rate at 12 Months: 46% (51 out of 110 patients; 95% CI: 36.9-56.1%).
- Kaplan-Meier Estimates: CR rate was 50% at 12 months and 41% at 24 months.
- Duration of Response (DOR): Median DOR was not reached but was greater than 27 months. Estimated probability of DOR was 63.5% at 12 months and 56.6% at 24 months.
- Progression-Free Survival (PFS): 97.3% at 12 months with no progression to muscle-invasive cancer.
- Cystectomy-Free Survival (CFS): 90.0% at 12 months.
- Reinduction: 50.0% of patients reinduced converted to CR; 64.3% remained in durable response after conversion.
Outlook, Risks, and Safety Profile
Safety and Tolerability:
- No Grade 3 or higher treatment-related adverse events (TRAEs) or deaths reported.
- Two patients (1.8%) experienced serious TRAEs (Grade 2): noninfective cystitis and clot retention.
- No treatment-related discontinuations observed; 97.3% of patients completed all protocol-defined treatments.
- Most common TRAEs (≥10%): bladder spasm (25.0%), pollakiuria (20.5%), dysuria (19.6%), micturition urgency (15.2%), and hematuria (13.4%).
- Future data may be inconsistent with current topline results.
- Risks include unexpected adverse side effects, inadequate efficacy, trial delays, and competitive developments.
- The company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis.
- Review the updated corporate presentation on the company website for context on the data.
- Monitor future filings for updated safety data and long-term follow-up results beyond the 24-month timepoint.
- Assess the regulatory pathway and potential filing timeline for marketing approval based on these Phase 3 results.
- Check the company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not contain financial data.